BiotechTube
Lantheus Holdings

Lantheus Holdings

LNTHApproved
700-800 employeeslantheus.com

Lantheus Holdings is a pioneer in the radiopharmaceutical space, dedicated to transforming patient care through precision diagnostics and targeted radiotherapeutics. The company has achieved significant commercial success with its flagship product, PYLARIFY, a PSMA PET imaging agent for prostate cancer, and maintains a robust pipeline of next-generation diagnostic and therapeutic candidates. With a strong commercial infrastructure, deep manufacturing expertise, and strategic partnerships, Lantheus is strategically positioned to capitalize on the rapidly growing market for targeted radiopharmaceuticals in oncology and cardiology.

Market Cap
$4.9B
-23.1% period
Pipeline
40
8 in Phase 3
Patents
—
Publications
20
indexed

LNTH · Stock Price

USD 76.4323.01 (-23.14%)

Historical price data

AI Company Overview

Lantheus Holdings is a pioneer in the radiopharmaceutical space, dedicated to transforming patient care through precision diagnostics and targeted radiotherapeutics. The company has achieved significant commercial success with its flagship product, PYLARIFY, a PSMA PET imaging agent for prostate cancer, and maintains a robust pipeline of next-generation diagnostic and therapeutic candidates. With a strong commercial infrastructure, deep manufacturing expertise, and strategic partnerships, Lantheus is strategically positioned to capitalize on the rapidly growing market for targeted radiopharmaceuticals in oncology and cardiology.

OncologyCardiology

Technology Platform

Integrated radiopharmaceutical platform encompassing targeted ligand discovery, radioisotope sourcing, GMP manufacturing, and a time-sensitive commercial distribution network for diagnostic and therapeutic products.

Pipeline

40
40 drugs in pipeline8 in Phase 3
DrugIndicationStageWatch
Definity® Vial for (Perflutren Lipid Microsphere) Injectable...Ventricular Ejection FractionApproved
3D HI and SHI of UCABreast CancerApproved
DEFINITY®Cardiovascular DiseaseApproved
Technetium Tc99m SestamibiMyocardial InfarctionApproved
Piflufolastat F 18 Intravenous Solution [PYLARIFY]Prostate CancerApproved

Funding History

2
Total raised:$286M
Debt$200MJun 15, 2021
IPO$86MJun 25, 2015

FDA Approved Drugs

8
NEURACEQNDAMar 19, 2014
DEFINITY RTNDAJul 31, 2001
DEFINITYNDAJul 31, 2001

Opportunities

Significant growth opportunities exist from expanding the label and usage of PYLARIFY, successfully launching PNT2002 as a best-in-class PSMA therapy, and leveraging the FAP-targeting platform for pan-cancer diagnostic and therapeutic applications.
The company's integrated platform also positions it as an attractive partner for other developers of radiopharmaceuticals.

Risk Factors

Key risks include clinical failure of late-stage pipeline candidates, intensifying competition from large pharma in the radiopharmaceutical space, complexities and potential disruptions in the radioisotope supply chain, and challenges in integrating the large POINT Biopharma acquisition.

Competitive Landscape

Lantheus competes with Novartis (Pluvicto) and other biotechs in prostate cancer therapeutics, and with other PSMA-PET diagnostic providers. Its main differentiation is its fully integrated U.S. commercial and manufacturing platform for both diagnostics and therapeutics, and the logistical advantages of its F-18 based diagnostic agent.